- Hemostemix (HEM) has closed the first tranche of its non-brokered private placement for gross proceeds of $192,000
- The offering consisted of 640,000 units for $0.30 per unit
- Proceeds from the offering will be used to pay current filing and regulatory fees, reduce debt, and begin production of ACP-01
- Hemostemix is an autologous stem cell therapy company
- Shares of Hemostemix Inc. (HEM) opened trading at C$0.31
Hemostemix (HEM) has closed the first tranche of its previously announced non-brokered private placement for gross proceeds of $192,000.
The offering consisted of 640,000 units for $0.30 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one additional common share for a period of 24 months from the closing of the offering.
Warrants are subject to an acceleration clause.
All securities issued will be subject to a four-month hold period.
The company paid eligible finders approximately $15,360 in cash and issued 51,200 finder’s options.
Proceeds from the offering will be used to pay finder fees in connection with the closing, current filing and regulatory fees, debt reduction and commencing the buildout of production of ACP-01.
Hemostemix is an autologous stem cell therapy company. The company has developed and is commercializing its lead product ACP-01 for treating CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
Shares of Hemostemix Inc. (HEM) opened trading at C$0.31.
